Novocure Limited shares rise 3.26% intraday after Ladenburg Thalmann initiates coverage with a Buy rating.

Novocure Limited rose 3.26% in intraday trading, with Ladenburg Thalmann initiating coverage on the stock with a Buy rating and a $30 price target. The firm highlighted NovoCure's development and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua, for the treatment of solid tumor cancers. The company's products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma, and pleural mesothelioma. NovoCure is also conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC), and pancreatic cancer.